

PRODUCT	SIZES	PACK SIZE	CONTAINS	PROVEN EFFICACY	COMMONLY USED FOR
TauroLock™	3mL amp 5mL amp 10mL VI	10 10 100	Taurolidine Citrate (4%)	Anti coagulative effectiveness ^{2,10} , patency ^{2,10} , antibacterial ^{1,2,3,8,9} , antifungal ^{11,12,14} , biofilm inhibition ² , catheter survival ¹ , low risk of resistance ¹³ , good tolerability ^{15,17,18,8,2,16}	Oncology parenteral nutrition dialysis for HIT patients
NutriLock™	3mL amp	10	Taurolidine	Antibacterial ^{7,20} , antifungal ^{3,12,13} , biofilm inhibition, catheter survival, low risk of resistance ⁷ , good tolerability ²⁰	Patients with known sensitivity to citrate
TauroLock™ HEP 100	3mL amp	10	Taurolidine Citrate (4%) Heparin (100 IU/mL)	Anti coagulative effectiveness, patency, antibacterial ^{21,22,23,24} , antifungal ^{3,12,13,21} , biofilm inhibition, catheter survival, low risk of resistance ⁷ , good tolerability ^{22,23}	Oncology parenteral nutrition lines with minimal blood use
TauroLock™ HEP 500	5mL amp	10	Taurolidine Citrate (4%) Heparin (500 IU/mL)	Anti coagulative effectiveness ³ , patency ³ , antibacterial ^{2,5,6,7} , antifungal ^{11,12,14} , biofilm inhibition ³ , catheter survival ³ , low risk of resistance ¹³ , good tolerability ^{15,17,18}	Haemodialysis
TauroLock™ Urokinase 25000 • TauroLock™ • Urokinase	5mL 25.000 IU	5	Taurolidine Citrate (4%) Urokinase (25.000 IU)	Thrombolytic effectiveness ^{4,5} , removal of biofilm ¹⁹ , anti coagulative effectiveness ^{4,5} , improvement of patency ^{4,5} , antibacterial ⁵ , antifungal ^{11,12,14} , biofilm inhibition ^{4,5} , catheter survival ^{4,5} , low risk of resistance ¹³ , good tolerability ^{15,17,18}	All therapy areas

*Amp = Ampoule, VI = Vial, HIT = Heparin-induced thrombocytopenia

Contact us for more information or training:

Tel: **+44 (0)845 437 9542**

Email: Taurolock@kimal.com

Kimal PLC, Clayfield Rd, Worcester WR4 0AD

TauroLock™ products are manufactured by TauroPharm GmbH

Scan the QR code to learn more
about TauroLock™ solutions.



References:

1. Reinmüller J, The influence of Taurolidine on physiological and pathological blood coagulation and implications for its use. *Zentralbl Chir* 1999;124 Suppl 4:13-8.
2. Torres-Viera C, Thauvin-Eliopoulos C, Wennerstein CB, Souli M, Sofia RD, Eliopoulos GM. Activities of Taurolidine in vitro and in experimental enterococcal endocarditis. *Antimicrob Agents Chemother* 2000; 44(6): 1720-4.
3. Wouters Y, Roosenboom B, Causevic E, Kievit W, Groenewoud H, Wanten G. Clinical Outcomes of Home Parenteral Nutrition Patients Using Taurolidine as Catheter Lock: A Long-Term Cohort Study. *Clin. Nutr.* 2019 Oct;38(5):2210-2218.
4. Gorman SP, McCafferty DF, et al. (1987). Reduced Adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. *J Appl Bacteriol* 62(4): 315-20.
5. Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, Mermel LA. Antimicrobial Activity of a Novel Catheter Lock Solution. *Antimicrob Agents Chemother* 2002;46(6):1674-1679.
6. Visek, J.; Ryskova, L.; Safranek, R.; Lasticova, M.; Blaha, V. In vitro comparison of efficacy of catheter locks in the treatment of catheter related blood stream infection. *Clin. Nutr. ESPEN* 2019, 30, 107-112.
7. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. *Nephrol Dial Transplant.* 2004 Jun;19(6):1546-51.
8. Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U. Randomized controlled trial of Taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. *J Hosp Infect.* 2012 Apr;80(4):304-9.
9. Lyszkowska M, Kowalewski G, Szymczak M, Polnik D, Mikolajczyk A, Kaliciński P. Effects of Prophylactic use of Taurolidine citrate Lock on the number of catheter related infections in children under 2 years of age undergoing surgery. *J Hosp Infect.* 2019 Oct;103(2):223-226
10. Handrup MM, Møller JK, Schrøder H. Central Venous Catheters and Catheter Locks in Children with Cancer: a prospective randomised trial of Taurolidine versus Heparin. *Pediatr Blood Cancer* 2013;60(8):1292-1298.
11. Tribler S, Brandt CF, Petersen JH, Fugisang KA, Staun M, Broebach P, Moser CE, Jeppesen PB. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomised, placebo-controlled trial. *Am J Clin Nutr* 2017;106(3):839-848.
12. Al-Ali F, Hamdy AF, Hamad A, Elsayed M, Iqbal Z, Elsayed A, Ibrahim R, Tolba H, Buanan H, Fawzy A. Safety and Efficacy of Taurolidine/Urokinase versus Taurolidine/Heparin as a tunnelled catheter lock solution in haemodialysis patients: A Prospective, Randomised, Controlled Study. *Nephrol Dial Transplant* 2018 Apr 1;33(4):619-626
13. Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikić Ž, Bieleś B, Schairer B, Reiter T, Eskandary F, Sunder-Plassmann G, Sengoelge G. Taurolidine-based catheter lock regimen significantly reduces over all costs, infection and dysfunction rates of tunnelled haemodialysis catheters. *Kidney Int.* 2018 Mar;93(3):753-760
14. Bueloni TNV, Marchi D, Caetano C, de Souza Cavalcante R, Amaral MLA, Ponce D. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunnelled catheters in haemodialysis patients: A quasi-experimental trial. *International journal of Infectious Diseases* 85(2019)16-21.
15. Shanks RMQ, Donegan NP, Graber ML, Buckingham SE, Zegans ME, Cheung AL, O'Toole GA. Heparin Stimulates Staphylococcus Aureus BioFilm Formation. *Infect Immun.* 2005 Aug;73(8):4596-606.
16. Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, Tordior J, Van Biesen W. Diagnosis, prevention and treatment of Haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). *NDT Plus.* 2010 Jun; 3(3):234-246.
17. Gerald McDonnell, A Denver Russell. Antiseptics and Disinfectants: Activity, Action, and Resistance. *Clin Microbio Rev.* 1999 Jan (1): 147-179
18. Landry DL, Braden GL, Gobeille SL, Haessler SL, Vaidya CK, Sweet SJ. Emergence of Gentamicin-Resistant Bacteremia in Haemodialysis Patients Receiving Gentamicin Lock Catheter Prophylaxis. 2010 *Clin J Am Soc Nephrol.* Oct;5(10):1799-804.
19. Hernández MJ, Soriano A, Filella X, Calvo M, Coll E, Rebled J, Poch E, Graterol F, Compte M, Maduell F, Fontserè N. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation. (2020) *Journal of Vascular Access* Jul 21.
20. Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G, Diggle P. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with haemodialysis. *Semin Dial.* 2012 Mar-Apr;25(2):233-8
21. Murray EC, Deighan C, Geddes C, Thomson PC. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients. *QJM.* 2014 Dec;107(12):995-1000.
22. Zhao Y, Li Z, Zhang L, Yang Y, Tang Y, Fu P. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. *Am J Kidney Dis.* 2014 Mar;63(3):479-90.
23. Diamanti A, Capriati T. Recurrent catheter related bloodstream infections by *Candida glabrata*: Successful treatment with Taurolidine. *Clinical Nutrition* 33 (2014) 367.
24. Olthof E.D, Rentenaar R.J, Rijs A.J.M.M, Wanten G.J.A. Absence of microbial adaptation to taurolidine in patients on home parenteral nutrition who related bloodstream infections and use taurolidine locks. *Clin Nutr.* 2013; 32: 538-542.